CME Group Inc. (CME) Stock Analysis
Is CME a good investment?
CME Group Inc. (CME) has a Plutrex AI rating of 65.0/100 as of November 02, 2026, indicating a Buy consensus. The stock is not classified as halal-compliant. Key strength: Unmatched profitability moat: net margin 63.3% (+117% vs. peers), operating margin 65.9% (+48% vs. peers), FCF $4.33B — CME retains 63 cents of every revenue dollar as profit, validating its near-monopoly exchange infrastructure; special dividends and buybacks are structurally secure. Main concern: Structural growth deficit vs. peers: forward EPS growth 6.8% is 79% below industry avg of 32.6%; PEG of 2.96x is 24% above peer average of 2.38x — CME pays a growth premium while delivering growth-deficit results, making growth-adjusted valuation the most critical ongoing risk.
Investment Summary
CME Group (current price $303.14) is one of the finest businesses in existence — net margin 63.3%, operating margin 65.9%, gross margin 82.8%, D/E of 0.14, and $4.33B annual FCF — but remains priced for near-perfection with limited upside. The analyst consensus target has materially upgraded from $294.60 to $321.43 (+9.1%), creating 6.0% upside vs. the stock's 3.2% price increase since the prior report — a meaningful improvement in risk/reward from the prior scenario where upside was essentially zero. However, the core valuation tension persists: PEG of 2.96x vs. peer average of 2.38x (24% premium), P/E of 24.86x on only 6.8% forward EPS growth, and near-term EPS growth lagging the industry by 79%. Q3 record activity, a Buy upgrade, and 92.6/100 news sentiment are genuine positives but cannot fully resolve the growth-adjusted valuation premium. This remains a HOLD for existing investors and a 'wait for better entry' for new buyers — the thesis is quality compounding, not near-term capital appreciation.
Key Strengths
- Unmatched profitability moat: net margin 63.3% (+117% vs. peers), operating margin 65.9% (+48% vs. peers), FCF $4.33B — CME retains 63 cents of every revenue dollar as profit, validating its near-monopoly exchange infrastructure; special dividends and buybacks are structurally secure
- Fortress balance sheet with D/E of only 0.14x (vs. peer avg 0.58x, 76% below industry) and $2.33B cash — combined with record Q3 ADV of 29.4M contracts and recent Buy upgrade, the business generates cash regardless of macro conditions
- Analyst target upgrade from $294.60 to $321.43 (+9.1%) materially improves risk/reward vs. 14 days ago when upside was near zero; record Q3 results and growing institutional crypto derivatives demand (CME Brazilian Real Futures volume record, Bitcoin futures positioning) validate the strategic moat
Key Concerns
- Structural growth deficit vs. peers: forward EPS growth 6.8% is 79% below industry avg of 32.6%; PEG of 2.96x is 24% above peer average of 2.38x — CME pays a growth premium while delivering growth-deficit results, making growth-adjusted valuation the most critical ongoing risk
- At $303.14 with DCF fair value of $270-$295, the stock trades above intrinsic value with only 6.0% upside to the $321.43 consensus target — insufficient margin of safety for new buyers given that forward EPS growth deceleration from 16.1% trailing to 6.8% forward has NOT been resolved
Plutrex 10-Factor AI Breakdown
Fundamental Analysis
CME's fundamentals split cleanly into two tiers. EXCEPTIONAL: Gross margin 82.8% (vs. industry avg 65.7%), operating margin 65.9% (vs. 44.4%), net margin 63.3% (vs. 29.2%), D/E 0.14 (vs. peer avg 0.58), FCF $4.33B, cash $2.33B — these are monopoly-quality metrics. ROE of 16.1% achieved with near-zero leverage is genuinely impressive, confirming true business quality rather than financial engineering. CONCERNING: Forward EPS growth of only 6.8% next year (vs. industry avg 32.6%) and 8.4% over 5 years (vs. 11.25% peer avg). This represents a deceleration from 16.1% trailing earnings growth. The P/E of 24.86x against 6.8% near-term EPS growth produces a PEG of 2.96x — implying the market prices in either a growth re-acceleration or a permanent quality premium that may not be fully justified. DCF using $4.33B FCF, 8.4% growth for 5 years, 6% terminal growth, 9% discount rate yields intrinsic value of $270-$295, suggesting mild overvaluation at $303.14.
News Sentiment
CME Group is riding a wave of record-breaking momentum heading into year-end, but investors should look beyond the headlines before celebrating. The exchange giant just reported record third-quarter activity with average daily volume hitting 29.4 million contracts — a figure that underscores CME's irreplaceable role as the world's premier risk management venue during turbulent geopolitical and electoral periods. The company's Brazilian Real Futures even set a new single-day volume record following election volatility, with an 11x spike in ADV that validates CME's 24-hour trading strategy in dramatic fashion. Adding fuel to the fire, CME received a fresh analyst upgrade to Buy, reflecting growing optimism about earnings prospects — and that optimism showed up in the analyst consensus price target jumping from $294.60 to $321.43, a 9% increase that meaningfully improves the stock's risk/reward profile. Meanwhile, a comparison piece weighing 'CME vs. Mastercard' highlighted the debate between CME's defensive cash generation and higher-growth financial peers, while a Crypto ETF regulatory story indirectly spotlights CME's growing Bitcoin futures franchise as institutional digital asset demand accelerates. The bottom line: CME's news flow is genuinely positive — record volumes, analyst upgrades, and crypto tailwinds — but existing investors benefit more than new buyers at today's price of $303.
Risk Assessment
Primary risk: multiple compression if forward EPS growth of 6.8% disappoints — a re-rating to 20x P/E (reasonable for 6-8% growers) implies ~$245, a 19% decline from current levels. Secondary risk: the 11.7% rally from $263 to $303 in the prior 14-day period followed by another 3.2% gain suggests momentum-driven buying that can reverse sharply. Mitigation: CME's $4.33B FCF and special dividend provide a fundamental income floor; the stop at $258 limits downside to ~7.3% from the entry midpoint. For existing holders, the FCF-backed income stream and quality moat justify continued holding through volatility. Macro tail risk: a sustained low-volatility, low-volume market environment would pressure CME's derivatives volumes and revenue, though the multi-asset diversification (interest rates, agricultural, FX, crypto) reduces single-product cyclicality.
Related Halal Stocks
Related Stocks
Frequently Asked Questions
Is CME a halal stock?
No, CME Group Inc. (CME) is currently not classified as halal by AAOIFI criteria.
What is Plutrex's AI rating for CME?
CME Group Inc. (CME) has a Plutrex AI rating of 65.0/100 with a Buy consensus, based on a 10-factor analysis covering financial health, growth, valuation, profitability, debt, analyst sentiment, technical momentum, insider confidence, news sentiment, and halal compliance.
Is CME a good investment?
According to Plutrex AI, CME has a Buy rating (65.0/100). For the full analysis including trading plan and risk assessment, see the detailed breakdown above.
How can I invest in CME?
US stocks like CME can be bought through international brokers such as Interactive Brokers, accessible to Arab investors. ElBarake provides comprehensive analysis plus AI-generated trading plans with entry points, stop losses, and profit targets.
What are the main risks of investing in CME?
Plutrex AI identifies the main risks for CME by analyzing valuation, debt, market sentiment, and macro factors. See the Risk Assessment section above for the full breakdown.